Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).

被引：0
|
作者：
Montgomery, Robert B.
Eisenberger, Mario A.
Rettig, Matthew
Chu, Franklin
Pili, Roberto
Stephenson, Joe
Vogelzang, Nicholas J.
Morrison, Jodie
Taplin, Mary-Ellen
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Johns Hopkins Univ, James Buchanan Brady Urol Inst, Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[4] San Bernadino Urol Associates, San Bernardino, CA USA
[5] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[6] Canc Ctr Carolinas, Greenville, SC USA
[7] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[8] US Oncol Res, Las Vegas, NV USA
[9] Tokai Pharmaceut, Boston, MA USA
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4665
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Re: Selective Inhibition of CYP17 with Abiraterone Acetate is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
    Schmid, Hans-Peter
    Engeler, Daniel S.
    EUROPEAN UROLOGY, 2009, 56 (04) : 744 - 745
  • [42] Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel
    Duran, Ignacio
    Montagut, Clara
    Calvo, Emiliano
    Galtes, Susana
    Navarrete, Alicia
    Rodriguez-Pascual, Jesus
    Hidalgo, Manuel
    Francisco Rodriguez-Moreno, Juan
    Cubillo, Antonio
    Garcia, Antonia
    Sanchez, Lorena
    Barbas, Coral
    Viqueira, Andrea
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [43] A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC)
    Pinski, Jacek K.
    Schally, Andrew V.
    Tsao-Wei, Denice D.
    Dorff, Tanya B.
    Groshen, Susan G.
    Xiong, Shigang
    Quinn, David I.
    Tai, Yu-Chong
    Engel, Juergen
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Clinical and Immunological Analysis of a Phase I Trial Evaluating MVA-BN®-PRO in patients with Non-metastatic Castration Resistant Prostate Cancer (CRPC)
    Legrand, Fatema A.
    McLeod, David
    Bilhartz, David
    Gittleman, Marc
    Adams, George
    Cochran, James
    Reiling, Richard
    Ruiz, Henry
    Karlin, Gary
    Owen, Rachel
    Nguyen, Anh-Tuan
    Hwang, Olivia
    Paranjpe, Gayatri
    Fernandez, Leilani
    Brand, Leslie
    Laus, Reiner
    Delcayre, Alain
    Godfrey, Wayne
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 900 - 901
  • [45] A phase Ib trial of enzalutamide with oral decitabine/cedazuridine in metastatic castration-resistant prostate cancer (CRPC).
    Roy, Arya Mariam
    Gopalakrishnan, Dharmesh
    Jatwani, Karan
    Green, Kelly
    Farmer, Bailey
    Jaiswal, Neha
    Attwood, Kristopher
    Levine, Ellis Glenn
    Beltran, Himisha
    Goodrich, David
    Chatta, Gurkamal S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS252 - TPS252
  • [46] A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer
    Peer, Cody J.
    Schmidt, Keith T.
    Kindrick, Jessica D.
    Eisner, Joel R.
    Brown, Victoria V.
    Baskin-Bey, Edwina
    Madan, Ravi
    Figg, William D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 759 - 770
  • [47] A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer
    Cody J. Peer
    Keith T. Schmidt
    Jessica D. Kindrick
    Joel R. Eisner
    Victoria V. Brown
    Edwina Baskin-Bey
    Ravi Madan
    William D. Figg
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 759 - 770
  • [48] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase II clinical trial
    Pan, C.
    Ghosh, P.
    Lara, P., Jr.
    Robles, D.
    Beckett, L.
    White, R. de Vere
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [49] Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
    Nakabayashi, Mari
    Werner, Lilian
    Courtney, Kevin D.
    Buckle, Geoffrey
    Oh, William K.
    Bubley, Glen J.
    Hayes, Julia H.
    Weckstein, Douglas
    Elfiky, Aymen
    Sims, Danny M.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    BJU INTERNATIONAL, 2012, 110 (11) : 1729 - 1735
  • [50] ANTITUMOUR ACTIVITY OF THE PARP INHIBITOR OLAPARIB IN UNSELECTED SPORADIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN THE TOPARP TRIAL
    Mateo, J.
    Hall, E.
    Sandhu, S.
    Omlin, A. G.
    Miranda, S.
    Carreira, S.
    Goodall, J.
    Gillman, A.
    Mossop, H.
    Ralph, C.
    Zafeiriou, Z.
    Lopez, R. Perez
    Tunariu, N.
    Ferraldeschi, R.
    Rodrigues, D. Nava
    Kunju, L. P.
    Robinson, D.
    Attard, G.
    Chinnaiyan, A.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2014, 25
12345